C4 Therapeutics (CCCC)
(Delayed Data from NSDQ)
$2.12 USD
+0.07 (3.41%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $2.11 -0.01 (-0.47%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, C4 Therapeutics, Inc. has a market cap of $145.57M, which represents its share price of $2.05 multiplied by its outstanding shares number of 71.01M. As a small-cap company, CCCC's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
CCCC 2.12 +0.07(3.41%)
Will CCCC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CCCC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CCCC
Ocugen (OCGN) Reports Q2 Loss, Misses Revenue Estimates
C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Tops Revenue Estimates
CCCC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Misses Revenue Estimates
C4 Therapeutics (CCCC) Loses -21.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
C4 Therapeutics (CCCC) Loses -26.18% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Other News for CCCC
C4 Therapeutics Holds Annual Stockholders Meeting
C4 Therapeutics: An Entry Point If There's Ever Going To Be One
Wasatch Ultra Growth Fund Q1 2025 Commentary
C4 Therapeutics Reports Q1 2025 Financial Results
C4 Therapeutics (CCCC) Exceeds Revenue Expectations and Advances Key Drug Development | CCCC ...